Perrigo-Elan Deal Takes A Step Forward With Irish High Court ApprovalAllegan-based Perrigo Co. (NYSE:PRGO) and Ireland's Elan Corp. plc (NYSE:ELN) Friday announced that the Irish High Court has approved Perrigo’s pending acquisition of Elan.
Perrigo Company Announces Quarterly DividendPerrigo Co. (NYSE: PRGO) announced that its board declared a quarterly dividend of 9 cents per share, payable Dec. 17 to shareholders of record on Nov. 29.
Perrigo Co. Selling $2.3 Billion In Debt To Finance Elan PurchaseThe Allegan generic pharmaceutical and store-brand health products maker Perrigo Co. Ltd., which moved its corporate registration to Ireland earlier this year, said it would offer debt totaling $2.3 billion with maturities in 2016, 2018, 2023 and 2043.
Perrigo Profits, Sales RiseThe generic pharmaceutical and store-brand helath products maker Perrigo Co. (NYSE: PRGO) Thursday reported net income of $111.4 million or $1.18 a share in the first fiscal quarter ended Sept. 28, up from $105.6 million or $1.12 a share in the first fiscal quarter a year earlier. Revenue was $933.4 million, up from $769.8 million a year earlier.
Perrigo Sets Date Of Shareholder Meeting To Approve Elan AcquisitionPerrigo Co. (NYSE: PRGO) announced that it has scheduled a shareholder meeting for Monday, Nov. 18 in connection with Perrigo's proposed previously announced acquisition of Elan Corp. (NYSE: ELN).
Perrigo Company Gets FDA Approval For Generic Zyrtec For Kids, Presents At ConferencesPerrigo Co. (NYSE: PRGO) announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for cetirizine hydrochloride oral solution USP, 1 mg/mL, bubble gum flavored, the store brand equivalent to Children's Zyrtec Allergy Syrup, 1 mg/mL, bubble gum flavored.
Perrigo Company Announces Quarterly DividendPerrigo Co. (NYSE: PRGO) announced that its board of directors declared a quarterly dividend of 9 cents per share.
Perrigo Receives FDA Tentative Approval For Generic Equivalent To PrandinPerrigo Co. (Nasdaq: PRGO) announced that it has received tentative approval from the United States Food & Drug Administration for its abbreviated new drug application for repaglinide tablets, the generic equivalent to Prandin Tablets.
Perrigo Buys Ophthalmic Products Of Fera For $93MThe Allegan-based generic and store-brand health products manufacturer Perrigo Co. said Monday it had purchased the ophthalmic sterile ointment and solution porfolio of Fera Pharmaceuticals LLC and its affiliates of Long Island, N.Y.
Perrigo Launches First-Ever Industry Marketing Campaign For Store Brand OTC MedicationsPerrigo Co. announced it has kicked off a broad industry marketing and communications campaign to raise awareness for, and consumer confidence in, generic over-the-counter medications sold at leading retailers -- also known as "store brand" OTCs.
Perrigo Reports Record Revenue; Acquisition Charges Ding ProfitsThe generic drug and store brand health products maker Perrigo Co. (Nasdaq: PRGO) Wednesday reported record revenue of $919.8 million in the third fiscal quarer ended March 30, up from $778 million a year earlier.
Perrigo Starting Shipments of Guaifenesin Extended-Release 600mgPerrigo Co. (Nasdaq: PRGO) Monday announced that it has begun shipments of Guaifenesin 600mg Extended-Release tablets in a launch to its retail and wholesale customers